Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, observational, retrospective analysing safety and efficacy of perampanel as a first add-on therapy with different anti-seizure drugs

Next Previous
Trial Profile

A multicentre, observational, retrospective analysing safety and efficacy of perampanel as a first add-on therapy with different anti-seizure drugs

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary) ; Antiepileptic drugs
  • Indications Absence epilepsy; Generalised seizures; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Therapeutic Use

Most Recent Events

  • 20 Jan 2021 New trial record
  • 01 Dec 2020 Primary endpoint has not been met. (the proportion of patients achieving 50 % reduction in seizure frequency at 12 months at least during the last 6 months (responders).)
  • 01 Dec 2020 Primary endpoint has been met. (the proportion of seizure-free patients at 12 months at least during the last 6 months)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top